Table 1.
Enrolment and baseline characteristics of 200 weight losing patients with unresectable pancreatic cancer
| Experimental group (n = 95) | Control group (n = 105) | |
| Enrolment characteristics | ||
| Sex (M:F) | 54:41 | 56:49 |
| Age (y) | 67 (1) | 68 (1) |
| Histological proof of diagnosis | 55 (58%) | 61 (58%) |
| Stage of disease | ||
| II | 31 (33%) | 40 (39%) |
| III | 14 (15%) | 21 (20%) |
| IV | 49 (52%) | 42 (41%) |
| Usual weight (kg) | 72.7 (1.2) | 74.7 (1.4) |
| Pancreatic enzyme supplementation | 30 (32%) | 29 (28%) |
| Baseline characteristics (0 weeks) | Experimental | Control |
| Weight at baseline (kg) | 60.3 (1.1) (n = 88) | 61.4 (1.2) (n = 97) |
| Duration of weight loss (weeks) | 26.0 (2.1) (n = 88) | 25.3 (2.0) (n = 96) |
| Rate of weight loss (kg/4 weeks) | 2.9 (0.2) (n = 88) | 3.2 (0.3) (n = 96) |
| % weight loss from usual weight | 17.9 (0.9) (n = 88) | 17.1 (0.8) (n = 97) |
| Body mass index (kg/m2) | 21.8 (0.4) (n = 88) | 22.0 (0.4) (n = 97) |
| Lean body mass (kg) | 43.3 (0.9) (n = 80) | 43.4 (0.9) (n = 91) |
| Karnofsky performance score | 74.9 (1.2) (n = 88) | 73.9 (1.0) (n = 98) |
| EQ-5Dindex | 0.62 (0.03) (n = 86) | 0.62 (0.03) (n = 91) |
| EQ-5Dvas | 52.3 (2.2) (n = 87) | 57.2 (1.9) (n = 96) |
| EORTC QLQ-C30 global HS | 48.8 (2.2) (n = 86) | 53.1 (2.2) (n = 95) |
| EORTC QLQ-C30 physical function | 64.1 (2.2) (n = 87) | 67.7 (2.3) (n = 96) |
| Meal intake (kcal/day) | 1504 (54) (n = 84) | 1613 (51) (n = 95) |
| Meal intake (g protein/day) | 60 (2) (n = 84) | 63 (2) (n = 95) |
Values are mean (SEM) or percentage of group (%).
HS, health score.